Archive: 08/06/2020
Empagliflozin—kidney protection regardless of an initial 'eGFR dip'
Empagliflozin (EMPA), a selective inhibitor of sodium/glucose cotransporter 2 (SGLT2 inhibitors, "gliflozines"), reduces CKD progression in type 2 diabetics (T2D) with cardiovascular disease, presumably by lowering intraglomerular ...
Jun 8, 2020
ANCA-associated vasculitis: The ADVOCATE study
ANCA-associated vasculitis (AAV) is a systemic disease involving the formation of special autoantibodies (so-called anti-neutrophil cytoplasmic antibodies/ANCA) and vascular inflammation. There are several diseases associated ...
Jun 8, 2020
Prophylaxis after relapse of ANCA-associated vasculitis
ANCA-associated vasculitis (AAV) is an autoimmune disease involving vascular inflammation and the formation of autoantibodies (anti-neutrophil cytoplasmic antibodies—ANCA). AAV diseases include a variety of conditions accompanied ...
Jun 8, 2020